PRESS RELEASES

Date Title View
Toggle Summary Chimerix Announces Positive ONC201 Data in Recurrent H3 K27M-mutant Diffuse Midline Glioma to Be Presented at the Society for Neuro-Oncology Annual Meeting
– Plenary Session Presentation on Saturday, November 20 – – Company to Host Conference Call at 8:30 a.m. ET on Monday, November 22 – DURHAM, N.C. , Nov. 19, 2021 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully
View HTML
Toggle Summary Chimerix to Present at Jefferies London Healthcare Conference
DURHAM, N.C. , Nov. 12, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX),a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman , Chief Executive Officer of Chimerix ,
View HTML
Toggle Summary Chimerix Announces Upcoming Presentations at the Society for Neuro-Oncology Annual Meeting 2021
DURHAM, N.C. , Nov. 11, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced upcoming data presentations at the Society for
View HTML
Toggle Summary Chimerix Reports Third Quarter 2021 Financial Results and Provides Operational Update
– Announced Positive Topline Results from ONC201 in Recurrent H3 K27M-mutant Glioma – – U.S. Food and Drug Administration (FDA) Published Article Summarizing Benefit-Risk Assessment of TEMBEXA for the Treatment of Smallpox – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C. , Nov.
View HTML
Toggle Summary Chimerix Announces Positive Topline Results for ONC201 in Recurrent H3 K27M-mutant Glioma
– Blinded Independent Central Review (BICR) of ONC201 Cohort Reported 20.0% Objective Response Rate (ORR) by RANO-HGG Criteria – – Compelling Durability of Responses with 11.2 Month Median Duration of Response (mDOR) in Addition to an 8.3 Month Median Time to Response (mTTR) – – Additional Data to
View HTML
Toggle Summary Chimerix to Present at Credit Suisse 30th Annual Healthcare Conference
DURHAM, N.C. , Nov. 01, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman , Chief Executive Officer of Chimerix ,
View HTML
Toggle Summary Chimerix to Report Third Quarter 2021 Financial Results and Provide an Operational Update on November 4, 2021
DURHAM, N.C. , Oct. 28, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing medicines for patients facing deadly diseases that meaningfully improves and extends their lives, today announced that it will host a live conference call and audio webcast on Thursday,
View HTML
Toggle Summary Chimerix to Present at H.C. Wainwright 23rd Annual Global Investment Conference
DURHAM, N.C. , Sept. 07, 2021 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman , Chief Executive Officer of Chimerix and Mike Andriole , Chief
View HTML
Toggle Summary Chimerix Reports Second Quarter 2021 Financial Results and Provides Operational Update
– Received U.S. Food and Drug Administration (FDA) Approval for TEMBEXA ® (brincidofovir) for the Treatment of Smallpox – – Blinded Independent Central Review (BICR) of ONC201 Registration Cohort in Recurrent H3 K27M-mutant Glioma Expected in Fourth Quarter 2021 – – Conference Call at 8:30 a.m.
View HTML
Toggle Summary Chimerix to Present at 2021 Wedbush PacGrow Healthcare Conference
DURHAM, N.C. , Aug. 03, 2021 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman , Chief Executive Officer, will participate in a panel discussion
View HTML